Gri Bio Inc. reported full year 2025 financial results, ending the year with cash and cash equivalents of approximately USD 8.2 million. In January 2026, the company raised an additional USD 6.5 million in gross proceeds through its At The Market offering, strengthening its balance sheet. Gri Bio expects its current cash position to fund operations into the first quarter of 2027. On the business front, Gri Bio highlighted positive topline results from its Phase 2a clinical study of GRI-0621 in idiopathic pulmonary fibrosis (IPF), reinforcing clinical proof-of-concept and demonstrating suppression of pro-fibrotic immune phenotypes. Additionally, new RNA-sequencing gene expression data showed a direct impact on fibrosis and lung repair biology. The company is progressing GRI-0803, focused on autoimmune indications with high unmet need, through IND-enabling studies, expanding its pipeline in autoimmune diseases. Management emphasized a focus on disciplined clinical execution and capital management, with ongoing efforts to advance GRI-0621 in IPF and GRI-0803 toward clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648455-en) on February 04, 2026, and is solely responsible for the information contained therein.